Cerebrolysin: what the human research actually shows
Cerebrolysin is the clearest case I know of where the number of RCTs looks impressive on paper, and the independent meta-analysis says the evidence does not hold up. That gap is the whole story.
Why I looked into this
Cerebrolysin kept showing up in stroke-recovery and dementia discussions with a weirdly specific claim attached: dozens of randomized trials, decades of use in Europe and Asia, yet somehow not approved in the US. That combination usually means one of two things. Either there is a regulatory quirk keeping a good drug off the American market, or the evidence looks stronger from a distance than it does up close.
I went to read the actual trials and the independent reviews. What I found is the cleanest example in the peptide world of the difference between volume of evidence and quality of evidence.
What Cerebrolysin actually is
Cerebrolysin is not a single peptide. It is a complex biological preparation made by enzymatically processing brain tissue from young pigs, which yields a mixture of low-molecular-weight peptide fragments and free amino acids. It was developed in Austria by Ebewe Pharma, now owned by Sandoz and Ever Neuro Pharma, and has been marketed since the 1970s.
Because it is a mixture derived from animal tissue, Cerebrolysin is closer in regulatory character to a biological product than to a defined synthetic peptide like Semaglutide or BPC-157. The exact composition varies between batches within controlled specifications, and the mechanism of action proposed by the manufacturer centers on neurotrophic-like and neuroprotective activity. It is given as an infusion, not as an oral product, which also shapes how and where it has been studied.
What the human research shows
Do published human trials exist?
Yes, and there are a lot of them. Cerebrolysin has been studied in randomized controlled trials across several decades, mostly for acute ischemic stroke, vascular dementia, Alzheimer disease, and traumatic brain injury.
This is one of the few peptides on this site where the honest answer to the first question is not “almost nothing.” The published human record includes multi-center trials with thousands of patients in aggregate. That is a meaningfully different starting point from most of the peptide landscape, and it deserves to be stated plainly before the caveats begin.
What evidence actually exists?
The most-cited human studies are:
- Ziganshina LE, Abakumova T, Hoyle CH. “Cerebrolysin for acute ischaemic stroke.” Cochrane Database of Systematic Reviews, 2018 and updates. A pooled analysis of 11 randomized trials with 2,855 participants. Main finding: no statistically robust benefit for death or dependence at the end of follow-up. The conclusion states the review does not support Cerebrolysin therapy for acute ischaemic stroke.
- Heiss WD et al. “Cerebrolysin in patients with acute ischemic stroke in Asia (CASTA).” Stroke, 2012. A large multicenter RCT across Asian centers. The primary efficacy endpoint was not met, although some secondary endpoints favored the treatment arm.
- Alvarez XA et al. Randomized trials in vascular dementia and mild-to-moderate Alzheimer disease reporting cognitive and global impression improvements on specific rating scales.
- Muresanu DF et al. “Cerebrolysin and Recovery After Stroke (CARS)” trial program, reporting motor recovery benefit on upper-limb outcomes at specific follow-up windows.
- Bornstein NM et al. Pooled analyses and review work summarizing mixed results across indications and trial populations.
What the research does not show
The research does NOT show:
- A robust, independently confirmed mortality or disability benefit in acute ischemic stroke. The Cochrane review is explicit on this point.
- A consistent effect size across regions. Trials run in some settings report larger benefits than trials run in others, which is a pattern that typically raises questions about design rather than answers about biology.
- Strong support from the major Western neurology guideline bodies. The European Federation of Neurological Societies guidance and American Academy of Neurology guidance have not endorsed routine use for stroke recovery.
- Evidence of disease modification in Alzheimer disease of the kind required for FDA approval of a dementia therapeutic.
- Any human data supporting the casual use as a general cognitive enhancer for healthy adults that circulates on biohacker forums. That use is well outside the trial population.
The honest summary is that Cerebrolysin has a large, uneven trial record, and the most rigorous independent synthesis of that record comes back negative on the main marketed indication.
Known safety signals in humans
In the published trials, Cerebrolysin is generally described as well tolerated. Reported adverse events include injection-site reactions, headache, dizziness, nausea, agitation, and occasional allergic-type reactions. Because the starting material is porcine brain tissue, hypersensitivity is a real category of concern for people with known allergies to pig-derived products, and the labeling in countries where it is approved reflects that.
There is no long-term safety record for the compound in US pharmacovigilance systems because it is not FDA approved. The available safety data comes from regions where post-market surveillance is structured differently, which means the signal that would show up in an FDA MedWatch-style system may simply not be visible in the literature.
FDA and legal status in the US
The regulatory story for Cerebrolysin is unusual. The product has been on the market in Austria and many other countries for decades. It is approved for indications like stroke and dementia across roughly fifty national regulators. Yet it has never received FDA approval, and there is no active US Phase 3 program aimed at securing approval.
This is not a case of a good drug being kept out of the US by regulatory obstruction. It is a case of the FDA applying evidence standards that the available trial data has not cleared for the main indications. Independent syntheses like the Cochrane review reach the same conclusion from a different angle.
How to evaluate a source: the safety framework
Why this section exists: people are going to look for sources whether I help or not. My goal here is harm reduction, not facilitation. I do not name vendors. I do not link to sellers. I am teaching you how to think about a source so you can have an informed conversation with a clinician.
- Licensed 503A compounding pharmacy
- Third-party certificate of analysis
- Requires a valid prescription
- US-based with verifiable physical address
- Transparent about what they compound and what they do not
- Anonymous crypto-only payment
- “Research use only” labeling loophole
- No COA or in-house testing only
- No physical address or phone contact
- Willingness to sell Category 2 substances for human use
The wrinkle for Cerebrolysin specifically
Cerebrolysin is different from most peptides on this site in a specific way: the authentic product is a trademarked, batch-controlled biological preparation manufactured by a specific company, not a chemically defined peptide that a lab can synthesize to spec. When people source Cerebrolysin in the US, they are either importing authentic foreign-market product, or they are buying something labeled “Cerebrolysin” from a research-use-only market that cannot possibly be verifying the actual identity of a complex animal-derived mixture.
That makes the source-safety problem here more severe, not less, than for a synthetic peptide. A research-use-only vial claiming to contain Cerebrolysin cannot be meaningfully authenticated by the buyer. A mass-spec identity check that works for a single-sequence peptide does not resolve “is this actually the Ever Neuro Pharma product.”
Cost reality
Authentic foreign-market Cerebrolysin, imported by individuals, typically costs significantly more per course than most research-use-only peptide offerings, because it is a finished pharmaceutical product with infusion-ready packaging. Research-use-only material labeled as Cerebrolysin is cheaper and should be treated with more suspicion rather than less, because the identity problem is harder.
Cost is not a reliable quality signal here either. The only genuinely reliable quality signal is whether the product is the actual manufacturer’s unit in its original packaging with traceable lot numbers, and even that is hard to verify outside a supervised clinical setting.
Questions worth asking any source
- Is this the authentic Ever Neuro Pharma or Sandoz product in its original manufacturer packaging with an intact lot number?
- Can you provide chain-of-custody documentation from the country of origin to the current location of the product?
- Are you a licensed 503A compounding pharmacy or a foreign pharmacy with a verifiable license?
- Do you require a valid prescription from a licensed clinician?
- What independent identity or integrity testing exists for the specific batch you are offering, and who performed it?
My honest take
Opinion, not evidence
This section is opinion. I am not endorsing use of this peptide. Everything above this line is sourced from the published record. Everything below is my personal perspective as one pseudonymous reader and one person who has used this peptide. Your situation is not my situation. Do not treat this as a recommendation.
I have not used Cerebrolysin. If I were considering it, the Cochrane review would stop me in a way that almost nothing else on this site stops me. This is not a case of “we do not have enough data.” This is a case of “we have a lot of data, and an independent team of reviewers with no commercial stake looked at all of it and concluded the evidence does not support the main marketed use.” Those are very different situations.
The counter-argument I take seriously is that some of the more recent trials on motor recovery and on specific cognitive outcomes look more consistent than the pooled stroke mortality data. That is a real point. It is also the kind of selective reading that every failing drug program has made at some stage, where the endpoint that worked this year becomes the endpoint that failed next year. I would not bet on a narrow positive finding inside a broadly negative evidence base.
For a healthy adult using Cerebrolysin off-label as a cognitive enhancer, there is essentially zero human evidence in that population. The trial populations were stroke patients, dementia patients, and TBI patients. Extrapolating from those groups to a 35-year-old looking for an edge is exactly the kind of evidence jump this site exists to push back against.
For someone curious, read the 2018 Cochrane review and the CASTA paper side by side. For someone considering use for a legitimate neurological indication, the conversation belongs with a neurologist who knows the global evidence, not with a biohacker group chat. For someone already using it, the source-verification story is uniquely weak, and I would treat that as the single most important practical risk.
Questions to ask your doctor
If you are considering Cerebrolysin, or if you are already using it and want to have an honest conversation with a clinician, these are the questions I would bring in with me.
- I have been reading about Cerebrolysin, including the 2018 Cochrane review that concluded the evidence does not support its use in acute ischemic stroke. How do you weigh that review against the individual positive trials?
- If I were to consider this compound for a specific neurological indication, what baseline workup would you want first, and what outcomes would you be measuring?
- Given that Cerebrolysin is derived from porcine brain tissue, what should I know about allergy risk and hypersensitivity screening before any exposure?
- Are there FDA-approved alternatives for the indication I am thinking about that we should fully rule out before considering an unapproved foreign product?
- If I were to obtain authentic product from a foreign pharmacy, how would you want the infusion supervised clinically, and what monitoring would you put in place?
- If I experienced an adverse reaction while using a porcine-derived neuropeptide mixture, what should I do first and who should I contact?
What to do next
Read the Cochrane review
Start with Ziganshina 2018 in the Cochrane Database. Read it before reading any summary that mentions Cerebrolysin positively.
Open the primer →Bring the packet to a neurologist
This is not a family-medicine conversation. A neurologist with access to the global evidence is the right clinician to weigh this decision.
Get the packet →Authenticity is the real problem
If you are going to use it, the hardest problem is verifying the product is actually what the label says. Use the 503A checklist and expect it to be harder to satisfy here.
Open the checklist →Sources
- Ziganshina LE, Abakumova T, Hoyle CH. “Cerebrolysin for acute ischaemic stroke.” Cochrane Database of Systematic Reviews. 2018. PMID 29687451.
- Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z; Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. “Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial.” Stroke. 2012;43(3):630-636. PMID 22282884.
- Muresanu DF, Heiss WD, Hoemberg V, et al. “Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial.” Stroke. 2016;47(1):151-159. PMID 26564102.
- Alvarez XA, Cacabelos R, Sampedro C, et al. “Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer’s disease.” Journal of Neural Transmission. 2011. PMID 21850442.
- Plosker GL, Gauthier S. “Cerebrolysin: a review of its use in dementia.” Drugs and Aging. 2009;26(11):893-915. PMID 19848437.
- European Federation of Neurological Societies and American Academy of Neurology guidance documents on stroke and dementia therapeutics, which have not endorsed routine use of Cerebrolysin for the main marketed indications.
I cite sources above to show the reader what is available to read. Inclusion does not imply endorsement of any claim. Every preclinical reference is flagged as animal or in-vitro only.
Related monographs
Semax
Another neuropeptide with a long Russian clinical history and a thin Western evidence base. Read alongside Cerebrolysin for a complete picture of this evidence category.
Selank
A short synthetic peptide from the same Russian research tradition as Semax, with similar evidence patterns. A useful comparison for the Cerebrolysin reader.
Pinealon
A short pineal tripeptide from the same research tradition as Epitalon, with essentially no independent human data. The contrast with Cerebrolysin’s large but negative record is instructive.